Krane Funds Advisors LLC increased its holdings in shares of Tempus AI, Inc. (NASDAQ:TEM – Free Report) by 218.2% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 28,230 shares of the company’s stock after purchasing an additional 19,358 shares during the quarter. Tempus AI accounts for about 0.1% of Krane Funds Advisors LLC’s investment portfolio, making the stock its 28th largest holding. Krane Funds Advisors LLC’s holdings in Tempus AI were worth $2,427,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of TEM. Citigroup Inc. increased its position in shares of Tempus AI by 209.4% in the third quarter. Citigroup Inc. now owns 24,792 shares of the company’s stock worth $2,001,000 after acquiring an additional 16,779 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new position in shares of Tempus AI during the 3rd quarter valued at $3,341,000. GSA Capital Partners LLP purchased a new stake in Tempus AI during the 3rd quarter worth $604,000. Vanguard Group Inc. increased its holdings in Tempus AI by 22.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after purchasing an additional 1,706,837 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its position in Tempus AI by 4.2% in the third quarter. State of New Jersey Common Pension Fund D now owns 33,111 shares of the company’s stock valued at $2,672,000 after purchasing an additional 1,323 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on TEM. HC Wainwright decreased their target price on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Needham & Company LLC boosted their price target on Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Morgan Stanley upped their price target on Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. BTIG Research lifted their price objective on shares of Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Finally, Mizuho assumed coverage on shares of Tempus AI in a research report on Thursday. They set an “outperform” rating and a $100.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $85.92.
Insider Activity
In other news, EVP Andrew Polovin sold 10,949 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $60.31, for a total value of $660,334.19. Following the completion of the sale, the executive vice president directly owned 126,918 shares in the company, valued at approximately $7,654,424.58. The trade was a 7.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Erik Phelps sold 9,464 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.43, for a total value of $562,445.52. Following the sale, the executive vice president directly owned 79,816 shares in the company, valued at approximately $4,743,464.88. This represents a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 596,035 shares of company stock valued at $37,505,125 over the last three months. Company insiders own 26.27% of the company’s stock.
Key Tempus AI News
Here are the key news stories impacting Tempus AI this week:
- Positive Sentiment: Launched HRD‑RNA algorithm to detect homologous recombination deficiency and added lung‑cancer screening via a partnership with Median Technologies, expanding Tempus’s diagnostic and screening addressable market; this could help grow commercial revenue and clinical adoption. Tempus AI Expands Cancer Workflow With HRD-RNA Launch And Lung Screening
- Positive Sentiment: Analyst attention increased as Mizuho initiated research coverage on TEM, which can improve visibility and liquidity for the stock; initiation often supports demand if the outlook is constructive. Tempus AI (NASDAQ:TEM) Research Coverage Started at Mizuho
- Positive Sentiment: Coverage and commentary highlight TEM’s imaging push (FDA‑cleared tools and Median partnership) as a growth vector — expanding beyond genomics into radiology can broaden product suites and recurring revenue opportunities. Here’s How Tempus AI Is Tapping the Imagining Space
- Neutral Sentiment: Market is watching upcoming earnings (preview coverage) — results and guidance will likely be a near‑term catalyst; until the report details revenue growth, margin trajectory, or bookings, investor reaction will hinge on execution vs. expectations. What’s Next: Tempus AI’s Earnings Preview
- Negative Sentiment: Large insider sales were reported across multiple executives (CEO, CFO, and EVPs totaling several million dollars of stock sold), which can spook investors and be interpreted as reduced insider confidence or portfolio diversification ahead of earnings. Tempus AI (NASDAQ:TEM) CEO Sells $566,407.60 in Stock CFO Sells $595,460.20 in Stock Insider Selling: EVP Sells $562,445.52 in Stock Insider Selling: EVP Sells $480,844.15 in Stock Tempus AI (NASDAQ:TEM) EVP Sells $660,334.19 in Stock
Tempus AI Stock Performance
Shares of Tempus AI stock opened at $57.29 on Tuesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32. The firm’s 50-day simple moving average is $62.13 and its 200-day simple moving average is $73.61. The firm has a market cap of $10.19 billion, a PE ratio of -48.14 and a beta of 5.22.
About Tempus AI
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
See Also
- Five stocks we like better than Tempus AI
- Elon Musk already made me a “wealthy man”
- Elon’s Secret AI Partner?
- Silver $500? The “Deficit Math” says it’s possible.
- Elon Musk: This Could Turn $100 into $100,000
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Want to see what other hedge funds are holding TEM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tempus AI, Inc. (NASDAQ:TEM – Free Report).
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
